Fluorine-18 P17 059
Alternative Names: [18F]D6-FP-DTBZ; [18F]D6FP; [18F]P17-059; Deuterated [18F]hexadeuterofluoropropyl-(+)-dihydrotetrabenazineLatest Information Update: 28 Jun 2025
At a glance
- Originator Five Eleven Pharma
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Parkinson's-disease(Diagnosis) in USA (IV, Injection)
- 19 Dec 2022 Five Eleven Pharma completes phase I clinical trial in Parkinson's disease (Diagnosis) in USA (IV) (NCT03903549)
- 05 May 2022 Phase-I clinical trials in Parkinson's disease (Diagnosis) in USA (IV) (NCT03903549)